Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2008

View Archived Issues

Lower diabetes rate seen with voclosporin compared to tacrolimus in renal transplant patients

Analyses reveal effects of sorafenib in hepatocellular carcinoma

Novel agents for bone disorders disclosed in recent Sungkyunkwan University patent

TorreyPines' NGX-267 meets primary endpoint in xerostomia phase II trial

Phase II study results reported for cardiovascular disease candidate VIA-2291

Questcor resubmits sNDA to FDA for H.P. Acthar Gel for infantile spasms

TransMolecular reaches SPA agreement with FDA for 131I-TM-601 phase III trial

Two pivotal HZT-501 phase III trials meet primary endpoints

NMRC submits revised IND to FDA to conduct Op RESUS trial of Biopure's Hemopure

Morphotek initiates phase II study of farletuzumab in platinum-resistant ovarian cancer

NPS initiates enrollment in phase III STEPS study of Gattex in short bowel syndrome

Mechanistically distinct drugs developed by PainCeptor, effective in pain models

New positive modulator of GABA-B receptors identified at Novartis

Recent Eisai and Scripps patents report novel antiinfective agents

Novel diagnostic agents imparted in recent patents

Twice-daily dosing of enzastaurin not feasible in glioma patients

Gene transfer of VEGF and HGF improves limb ischemia

HIV candidate VCH-286 safe, well tolerated in phase I study

Atorvastatin/fenofibrate tablet more effective than components in dyslipidemia

Azarga approved by EMEA for glaucoma or ocular hypertension

FDA grants orphan drug designation for antineoplaston treatment for gliomas

Geron initiates phase I vaccine candidate trial targeting telomerase

Genta receives FDA complete response letter for Genasense in CLL

Sucampo completed enrollment and initial dosing in two phase III trials of Amitiza in OBD

Eisai to initiate head-to-head clinical trial of Dacogen and Vidaza in MDS

FDA grants approval to PharmaEngine's IND for phase II study of PEP-02 in pancreatic cancer

Wyeth submits MAA in Europe for13-valent vaccine for pneumococcal disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.